Moleculin Biotech (MBRX) to Post Quarterly Earnings on Tuesday

Moleculin Biotech (NASDAQ:MBRX) is expected to release its Q2 2026 results before the market opens on Tuesday, August 11th. Analysts expect Moleculin Biotech to post earnings of ($1.6050) per share for the quarter. Interested persons may visit the the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Wednesday, August 12, 2026 at 4:00 PM ET.

Moleculin Biotech (NASDAQ:MBRX) last issued its earnings results on Thursday, May 14th. The company reported ($3.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.33) by ($1.21). On average, analysts expect Moleculin Biotech to post $-5 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Moleculin Biotech Price Performance

MBRX traded down $0.01 on Tuesday, reaching $0.41. 1,736,190 shares of the stock were exchanged, compared to its average volume of 520,607. The company’s 50-day moving average price is $2.41 and its 200 day moving average price is $2.73. The firm has a market capitalization of $2.20 million, a PE ratio of -0.02 and a beta of 1.84. Moleculin Biotech has a fifty-two week low of $0.16 and a fifty-two week high of $18.25.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Moleculin Biotech stock. Jane Street Group LLC bought a new stake in shares of Moleculin Biotech, Inc. (NASDAQ:MBRX) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 22,550 shares of the company’s stock, valued at approximately $75,000. Jane Street Group LLC owned 1.11% of Moleculin Biotech as of its most recent SEC filing. 15.52% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on MBRX shares. Wall Street Zen downgraded shares of Moleculin Biotech from a “sell” rating to a “strong sell” rating in a report on Saturday, May 16th. Weiss Ratings restated a “sell (e+)” rating on shares of Moleculin Biotech in a research report on Friday, July 17th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Moleculin Biotech currently has an average rating of “Hold” and an average price target of $22.00.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc is a clinical-stage pharmaceutical company focused on the development of novel therapies for the treatment of highly resistant tumors and viral infections. The company’s research platform centers on the design and synthesis of drug candidates that target key cellular pathways in cancer cells and viral replication processes. By leveraging a proprietary chemistry approach, Moleculin aims to address diseases that have limited therapeutic options and high unmet medical need.

The company’s pipeline includes multiple product candidates at various stages of development.